Synthetic curcumin analogs as inhibitors of β -amyloid peptide aggregation: Potential therapeutic and diagnostic agents for Alzheimer’s disease

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 13, 2015, Pages 1110-1121

  Bukhari, Syed Nasir Abbas ^a   Jantan, Ibrahim ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Alzheimer s disease; Anti amyloid effect; Brain; Neuroprotective effect; Synthetic curcumin analogs; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; NEUROPROTECTIVE AGENT; PROTEIN AGGREGATE;

ADAPTATION; ALZHEIMER DISEASE; ARTICLE; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; ELECTRON MICROSCOPY; HUMAN; INFLAMMATION; NEAR INFRARED SPECTROSCOPY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN AGGREGATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CURCUMIN; HUMANS; NEUROPROTECTIVE AGENTS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84947792074     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955751513150923101841     Document Type: Article

References (88)

1. [1] Lahiri, D.K.; Farlow, M.R.; Greig, N.H.; Sambamurti, K., Currentdrug targets for Alzheimer's disease treatment. Drug Dev. Res.,2002, 56(3), 267-281.
2. [2] Cummings, J. L., Alzheimer's disease. New Engl. J. Med., 2004,351(1), 56-67.
3. [3] Louw, C.; Gordon, A.; Johnston, N.; Mollatt, C.; Bradley, G.; Whiteley, C.G., Arginine deiminases: therapeutic tools in theetiology and pathogenesis of Alzheimer's disease. J. Enzy Inhib.Med. Chem., 2007, 22(1), 121-6.
4. [4] Hoyer, S., Brain glucose and energy metabolism abnormalities insporadic Alzheimer disease. Causes and consequences: an update.Exp. Gerontol., 2000, 35(9-10), 1363-1372.
5. [5] Bird, T. D., Genetic factors in Alzheimer's disease. New Engl. J.Med., 2005, 352(9), 862-4.
6. [6] World Alzheimer Report 2013 Alzheimer’s Disease International,2013, 1.
7. [7] Wu, T.-Y.; Chen, C.-P.; Jinn, T.-R., Traditional Chinese medicinesand Alzheimer’s disease. Taiwanese J. Obstetr. Gynecol., 2011,50(2), 131-135.
8. [8] Stafford, G.I.; Pedersen, M. E.; van Staden, J.; Jäger, A.K., Reviewon plants with CNS-effects used in traditional South Africanmedicine against mental diseases. J. Ethnopharmacol., 2008,119(3), 513-537.
9. [9] Howes, M.-J. R.; Houghton, P.J., Plants used in Chinese and Indiantraditional medicine for improvement of memory and cognitivefunction. Pharmacol. Biochem. Behav., 2003, 75(3), 513-527.
10. [10] Guo, Z.R., [Modification of natural products for drug discovery]. Yaoxue xue bao = Acta pharmaceutica Sinica, 2012, 47(2), 144-57.
11. [11] Valli, M.; Pivatto, M.; Danuello, A.; Castro-Gamboa, I.; Silva, D.H.S.; Cavalheiro, A.J.; Araújo, Â.R.; Furlan, M.; Lopes, M.N.; Bolzani, V.D.S., Tropical biodiversity: has it been a potentialsource of secondary metabolites useful for medicinal chemistry?Química Nova, 2012, 35, 2278-2287.
12. [12] Kim, D. S.H.L.; Park, S.-Y.; Kim, J.-Y., Curcuminoids from Curcumalonga L. (Zingiberaceae) that protect PC12 rat pheochromocytoma andnormal human umbilical vein endothelial cells from βA(1–42) insult.Neurosci. Lett., 2001, 303(1), 57-61.
13. [13] Potter, P. E., Curcumin: a natural substance with potential efficacyin Alzheimer’s disease. J. Exp. Pharmacol., 2013, 5, 23-31.
14. [14] Mancuso, C.; Siciliano, R.; Barone, E., Curcumin and AlzheimerDisease: This Marriage Is Not to Be Performed. J. Biol. Chem.,2011, 286(3), le3.
15. [15] Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L., A potential role of the curry spice curcumin inAlzheimer's disease. Curr. Alzheimer Res., 2005, 2(2), 131-6.
16. [16] Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol.Pharmaceut., 2007, 4(6), 807-18.
17. [17] Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y., Phase Iclinical trial of curcumin, a chemopreventive agent, in patients withhigh-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4B),2895-900.
18. [18] Shoba, G.; Joy, D.; Joseph, T.; Majeed, M.; Rajendran, R.; Srinivas, P. S., Influence of piperine on the pharmacokinetics ofcurcumin in animals and human volunteers. Planta Medica, 1998,64 (4), 353-6.
19. [19] Belkacemi, A.; Doggui, S.; Dao, L.; Ramassamy, C., Challengesassociated with curcumin therapy in Alzheimer disease. Exp. Rev.Mol. Med., 2011, 13, e34.
20. [20] Chen, S.-Y.; Chen, Y.; Li, Y.-P.; Chen, S.-H.; Tan, J.-H.; Ou, T.-M.; Gu, L.-Q.; Huang, Z.-S., Design, synthesis, and biologicalevaluation of curcumin Analogs as multifunctional agents for thetreatment of Alzheimer’s disease. Bioorg. Med. Chem., 2011,19(18), 5596-5604.
21. [21] Bolognesi, M. L.; Bartolini, M.; Tarozzi, A.; Morroni, F.; Lizzi, F.; Milelli, A.; Minarini, A.; Rosini, M.; Hrelia, P.; Andrisano, V.; Melchiorre, C., Multitargeted drugs discovery: Balancing antiamyloidand anticholinesterase capacity in a single chemical entity.Bioorg. Med. Chem. Lett., 2011, 21(9), 2655-2658.
22. [22] Cohen, A. S., Marrink, J., and Van Rijswijk, M. H. Ed, Generalintroduction and a brief history of the amyloid fibril. Amyloidosis,Nijhoff, Dordrecht, 1986, 3-19.
23. [23] Haass, C.; Schlossmacher, M. G.; Hung, A. Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B. L.; Lieberburg, I.; Koo, E. H.; Schenk, D.; Teplow, D. B.; et al., Amyloid beta-peptide is produced bycultured cells during normal metabolism. Nature, 1992, 359(6393),322-5.
24. [24] Seubert, P.; Vigo-Pelfrey, C.; Esch, F.; Lee, M.; Dovey, H.; Davis, D.; Sinha, S.; Schlossmacher, M.; Whaley, J.; Swindlehurst, C.; et al., Isolation and quantification of soluble Alzheimer's beta-peptidefrom biological fluids. Nature, 1992, 359(6393), 325-7.
25. [25] Shoji, M.; Golde, T. E.; Ghiso, J.; Cheung, T. T.; Estus, S.; Shaffer, L. M.; Cai, X. D.; McKay, D. M.; Tintner, R.; Frangione, B et al.,Production of the Alzheimer amyloid beta protein by normalproteolytic processing. Science (New York, N.Y.), 1992, 258(5079),126-9.
26. [26] Citron, M.; Oltersdorf, T.; Haass, C.; McConlogue, L.; Hung, A.Y.; Seubert, P.; Vigo-Pelfrey, C.; Lieberburg, I.; Selkoe, D. J., Mutation of the beta-amyloid precursor protein in familialAlzheimer's disease increases beta-protein production. Nature,1992, 360(6405), 672-4.
27. [27] Cai, X. D.; Golde, T. E.; Younkin, S. G., Release of excess amyloidbeta protein from a mutant amyloid beta protein precursor. Science(New York, N.Y.), 1993, 259(5094), 514-6.
28. [28] Suzuki, N.; Cheung, T. T.; Cai, X. D.; Odaka, A.; Otvos, L., Jr.; Eckman, C.; Golde, T. E.; Younkin, S. G., An increased percentageof long amyloid beta protein secreted by familial amyloid betaprotein precursor (beta APP717) mutants. Science (New York,N.Y.), 1994, 264(5163), 1336-40.
29. [29] Bentahir, M.; Nyabi, O.; Verhamme, J.; Tolia, A.; Horre, K.; Wiltfang, J.; Esselmann, H.; De Strooper, B., Presenilin clinicalmutations can affect gamma-secretase activity by differentmechanisms. J. Neurochem., 2006, 96 (3), 732-42.
30. [30] Kumar-Singh, S.; Theuns, J.; Van Broeck, B.; Pirici, D.; Vennekens, K.; Corsmit, E.; Cruts, M.; Dermaut, B.; Wang, R.; Van Broeckhoven, C., Mean age-of-onset of familial alzheimerdisease caused by presenilin mutations correlates with bothincreased Abeta42 and decreased Abeta40. Human Mutation, 2006,27 (7), 686-95.
31. [31] Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D., APP locusduplication causes autosomal dominant early-onset Alzheimerdisease with cerebral amyloid angiopathy. Nat. Gene., 2006, 38 (1),24-6.
32. [32] Castano, E. M.; Ghiso, J.; Prelli, F.; Gorevic, P. D.; Migheli, A.; Frangione, B., In vitro formation of amyloid fibrils from twosynthetic peptides of different lengths homologous to Alzheimer'sdisease beta-protein. Biochem. Biophy. Res. Comm., 1986, 141 (2),782-9.
33. [33] Kirschner, D. A.; Inouye, H.; Duffy, L. K.; Sinclair, A.; Lind, M.; Selkoe, D. J., Synthetic peptide homologous to beta protein fromAlzheimer disease forms amyloid-like fibrils in vitro. Proc. Nat.Acad. Sci. USA, 1987, 84 (19), 6953-7.
34. [34] Siemers, E.; DeMattos, R. B.; May, P. C.; Dean, R. A., Role ofbiochemical Alzheimer's disease biomarkers as end points inclinical trials. Biomark. Med., 2010, 4 (1), 81-9.
35. [35] Yin, Y. I.; Bassit, B.; Zhu, L.; Yang, X.; Wang, C.; Li, Y. M.,{gamma}-Secretase Substrate Concentration Modulates theAbeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMERDISEASE. J. Biol. Chem., 2007, 282 (32), 23639-44.
36. [36] Barnham, K. J.; Masters, C. L.; Bush, A. I., Neurodegenerativediseases and oxidative stress. Nat. Rev. Drug Discov., 2004, 3 (3),205-214.
37. [37] Nie, Q.; Du, X. G.; Geng, M. Y., Small molecule inhibitors ofamyloid beta peptide aggregation as a potential therapeutic strategyfor Alzheimer's disease. Acta pharmacologica Sinica, 2011, 32 (5),545-51.
38. [38] Lambert, M. P.; Barlow, A. K.; Chromy, B. A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T. E.; Rozovsky, I.; Trommer, B.; Viola, K. L.; Wals, P.; Zhang, C.; Finch, C. E.; Krafft, G. A.; Klein, W. L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Nat. Acad.Sci. USA., 1998, 95 (11), 6448-53.
39. [39] Cleary, J. P.; Walsh, D. M.; Hofmeister, J. J.; Shankar, G. M.; Kuskowski, M. A.; Selkoe, D. J.; Ashe, K. H., Natural oligomers ofthe amyloid-beta protein specifically disrupt cognitive function.Nat. Neurosci., 2005, 8(1), 79-84.
40. [40] Walsh, D. M.; Selkoe, D. J., Aβ Oligomers – a decade of discovery.J. Neurochem., 2007, 101 (5), 1172-1184.
41. [41] Haass, C.; Selkoe, D.J., Soluble protein oligomers inneurodegeneration: lessons from the Alzheimer's amyloid betapeptide.Nature reviews. Mol. Cell Biol., 2007, 8(2), 101-12.
42. [42] Carrell, R. W.; Mushunje, A.; Zhou, A., Serpins show structuralbasis for oligomer toxicity and amyloid ubiquity. FEBS Lett., 2008,582 (17), 2537-41.
43. [43] Pahnke, J.; Walker, L. C.; Scheffler, K.; Krohn, M., Alzheimer'sdisease and blood-brain barrier function-Why have anti-betaamyloidtherapies failed to prevent dementia progression?Neurosci. Biobehav. Rev., 2009, 33 (7), 1099-108.
44. [44] Dasilva, K. A.; Shaw, J. E.; McLaurin, J., Amyloid-betafibrillogenesis: structural insight and therapeutic intervention. Exp.Neurol., 2010, 223 (2), 311-21.
45. [45] Findeis, M. A., The role of amyloid beta peptide 42 in Alzheimer'sdisease. Pharmacol. Therap., 2007, 116 (2), 266-86.
46. [46] De Felice, F.G.; Ferreira, S.T., Beta-amyloid production,aggregation, and clearance as targets for therapy in Alzheimer'sdisease. Cell. Mol. Neurobiol., 2002, 22 (5-6), 545-63.
47. [47] Greenberg, S. M.; Grabowski, T.; Gurol, M. E.; Skehan, M. E.; Nandigam, R. N.; Becker, J. A.; Garcia-Alloza, M.; Prada, C.; Frosch, M. P.; Rosand, J.; Viswanathan, A.; Smith, E. E.; Johnson, K. A., Detection of isolated cerebrovascular beta-amyloid withPittsburgh compound B. Ann. Neurol., 2008, 64 (5), 587-91.
48. [48] Look, G. C.; Jerecic, J.; Cherbavaz, D. B.; Pray, T. R.; Breach, J.C.; Crosier, W. J.; Igoudin, L.; Hironaka, C. M.; Lowe, R. M.; McEntee, M.; Ruslim-Litrus, L.; Wu, H. M.; Zhang, S.; Catalano, S. M.; Goure, W. F.; Summa, D.; Krafft, G. A., Discovery ofADDL--targeting small molecule drugs for Alzheimer's disease.Curr. Alzheimer Res., 2007, 4 (5), 562-7.
49. [49] Singh, S.; Khar, A., Biological effects of curcumin and its role incancer chemoprevention and therapy. Anti-cancer Agents Med.Chem., 2006, 6 (3), 259-70.
50. [50] Egan, M. E.; Pearson, M.; Weiner, S. A.; Rajendran, V.; Rubin, D.; Glockner-Pagel, J.; Canny, S.; Du, K.; Lukacs, G. L.; Caplan, M.J., Curcumin, a major constituent of turmeric, corrects cysticfibrosis defects. Science (New York, N.Y.), 2004, 304 (5670), 600-2.
51. [51] Mall, M.; Kunzelmann, K., Correction of the CF defect bycurcumin: hypes and disappointments. BioEssays : news andReviews in Molecular, Cellular and Developmental Biology, 2005,27 (1), 9-13.
52. [52] Fiala, M.; Liu, P. T.; Espinosa-Jeffrey, A.; Rosenthal, M. J.; Bernard, G.; Ringman, J. M.; Sayre, J.; Zhang, L.; Zaghi, J.; Dejbakhsh, S.; Chiang, B.; Hui, J.; Mahanian, M.; Baghaee, A.; Hong, P.; Cashman, J., Innate immunity and transcription ofMGAT-III and Toll-like receptors in Alzheimer's disease patientsare improved by bisdemethoxycurcumin. Proc. Nat. Acad. Sci.USA, 2007, 104 (31), 12849-54.
53. [53] Hsu, C. H.; Cheng, A. L., Clinical studies with curcumin. Adv. Exp.Med. Biol., 2007, 595, 471-80.
54. [54] Miriyala, S.; Panchatcharam, M.; Rengarajulu, P., Cardioprotectiveeffects of curcumin. Adv. Exp. Med. Biol., 2007, 595, 359-77.
55. [55] Weisberg, S. P.; Leibel, R.; Tortoriello, D. V., Dietary curcuminsignificantly improves obesity-associated inflammation anddiabetes in mouse models of diabesity. Endocrinology, 2008,149(7), 3549-58.
56. [56] Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M.R.; Ambegaokar, S. S.; Chen, P. P.; Kayed, R.; Glabe, C. G.; Frautschy, S. A.; Cole, G. M., Curcumin inhibits formation ofamyloid beta oligomers and fibrils, binds plaques, and reducesamyloid in vivo. J. Biol. Chem., 2005, 280(7), 5892-901.
57. [57] Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M., Curcumin haspotent anti-amyloidogenic effects for Alzheimer's beta-amyloidfibrils in vitro. J. Neurosci. Res., 2004, 75(6), 742-50.
58. [58] Kim, H.; Park, B. S.; Lee, K. G.; Choi, C. Y.; Jang, S. S.; Kim, Y.H.; Lee, S. E., Effects of naturally occurring compounds on fibrilformation and oxidative stress of beta-amyloid. J. Agri. FoodChem., 2005, 53(22), 8537-41.
59. [59] Re, F.; Airoldi, C.; Zona, C.; Masserini, M.; La Ferla, B.; Quattrocchi, N.; Nicotra, F., Beta amyloid aggregation inhibitors:small molecules as candidate drugs for therapy of Alzheimer'sdisease. Curr. Med. Chem., 2010, 17(27), 2990-3006.
60. [60] Ganguli, M.; Dodge, H. H.; Chen, P.; Belle, S.; DeKosky, S. T.,Ten-year incidence of dementia in a rural elderly US communitypopulation: the MoVIES Project. Neurology, 2000, 54(5), 1109-16.
61. [61] Reinke, A. A.; Gestwicki, J. E., Structure-activity relationships ofamyloid beta-aggregation inhibitors based on curcumin: influenceof linker length and flexibility. Chem. Biol. Drug Design, 2007,70(3), 206-15.
62. [62] Anand, P.; Thomas, S.G.; Kunnumakkara, A.B.; Sundaram, C.; Harikumar, K.B.; Sung, B.; Tharakan, S.T.; Misra, K.; Priyadarsini, I.K.; Rajasekharan, K.N.; Aggarwal, B.B., Biological activities ofcurcumin and its Analogs (Congeners) made by man and MotherNature. Biochem. Pharmacol., 2008, 76 (11), 1590-611.
63. [63] Bernabe-Pineda, M.; Ramirez-Silva, M.T.; Romero-Romo, M.; Gonzalez-Vergara, E.; Rojas-Hernandez, A., Determination ofacidity constants of curcumin in aqueous solution and apparent rateconstant of its decomposition. Spectrochimica acta. Part A, Mol.Biomol. Spectroscopy, 2004, 60 (5), 1091-7.
64. [64] Wang, Y.J.; Pan, M.H.; Cheng, A.L.; Lin, L.I.; Ho, Y.S.; Hsieh, C.Y.; Lin, J.K., Stability of curcumin in buffer solutions andcharacterization of its degradation products. J. Pharmaceut.Biomed. Analysis, 1997, 15(12), 1867-76.
65. [65] Tonnesen, H. H.; Karlsen, J., Studies on curcumin andcurcuminoids. VI. Kinetics of curcumin degradation in aqueoussolution. Zeitschrift fur Lebensmittel-Untersuchung und –Forschung, 1985, 180(5), 402-4.
66. [66] Mourtas, S.; Canovi, M.; Zona, C.; Aurilia, D.; Niarakis, A.; LaFerla, B.; Salmona, M.; Nicotra, F.; Gobbi, M.; Antimisiaris, S. G., Curcumin-decorated nanoliposomes with very high affinity foramyloid-beta1-42 peptide. Biomaterials, 2011, 32(6), 1635-45.
67. [67] Said Hassane, F.; Frisch, B.; Schuber, F., Targeted liposomes:convenient coupling of ligands to preformed vesicles using "clickchemistry". Bioconj. Chem., 2006, 17(3), 849-54.
68. [68] Cavalli, S.; Tipton, A. R.; Overhand, M.; Kros, A., The chemicalmodification of liposome surfaces via a copper-mediated [3 + 2]azide-alkyne cycloaddition monitored by a colorimetric assay.Chem. communications (Cambridge, England), 2006, 30, 3193-5.
69. [69] Hein, C. D.; Liu, X. M.; Wang, D., Click chemistry, a powerfultool for pharmaceutical sciences. Pharmaceut. Res., 2008, 25(10),2216-30.
70. [70] Frisch, B.; Hassane, F. S.; Schuber, F., Conjugation of ligands tothe surface of preformed liposomes by click chemistry. Met. Mol.Biol. (Clifton, N.J.), 2010, 605, 267-77.
71. [71] Konno, H.; Endo, H.; Ise, S.; Miyazaki, K.; Aoki, H.; Sanjoh, A.; Kobayashi, K.; Hattori, Y.; Akaji, K., Synthesis and evaluation ofcurcumin derivatives toward an inhibitor of beta-site amyloidprecursor protein cleaving enzyme 1. Bioorg. Med. Chem. Lett.,2014, 24(2), 685-690.
72. [72] Yanagisawa, D.; Shirai, N.; Amatsubo, T.; Taguchi, H.; Hirao, K.; Urushitani, M.; Morikawa, S.; Inubushi, T.; Kato, M.; Kato, F.; Morino, K.; Kimura, H.; Nakano, I.; Yoshida, C.; Okada, T.; Sano, M.; Wada, Y.; Wada, K.-N.; Yamamoto, A.; Tooyama, I., Relationship between the tautomeric structures of curcuminderivatives and their Aβ-binding activities in the context oftherapies for Alzheimer's disease. Biomaterials, 2010, 31(14),4179-4185.
73. [73] Yanagisawa, D.; Amatsubo, T.; Morikawa, S.; Taguchi, H.; Urushitani, M.; Shirai, N.; Hirao, K.; Shiino, A.; Inubushi, T.; Tooyama, I., In vivo detection of amyloid beta deposition using(1)(9)F magnetic resonance imaging with a (1)(9)F-containingcurcumin derivative in a mouse model of Alzheimer's disease.Neuroscience, 2011, 184, 120-7.
74. [74] Xiao, Z.; Lin, L.; Liu, Z.; Ji, F.; Shao, W.; Wang, M.; Liu, L.; Li, S.; Li, F.; Bu, X., Potential therapeutic effects of curcumin:Relationship to microtubule-associated proteins 2 in Aβ1–42 insult.Brain Res., 2010, 1361(0), 115-123.
75. [75] Ouberai, M.; Dumy, P.; Chierici, S.; Garcia, J., Synthesis andbiological evaluation of clicked curcumin and clicked KLVFFAconjugates as inhibitors of beta-amyloid fibril formation.Bioconjugate Chem., 2009, 20(11), 2123-32.
76. [76] Chojnacki, J. E.; Liu, K.; Yan, X.; Toldo, S.; Selden, T.; Estrada, M.; Rodriguez-Franco, M. I.; Halquist, M. S.; Ye, D.; Zhang, S., Discovery of 5-(4-Hydroxyphenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide as a Neuroprotectant forAlzheimer's Disease by Hybridization of Curcumin and Melatonin.ACS Chem. Neurosci., 2014, 5(8), 690-9.
77. [77] Cui, M.; Ono, M.; Kimura, H.; Liu, B.; Saji, H., Synthesis andstructure-affinity relationships of novel dibenzylideneacetonederivatives as probes for beta-amyloid plaques. J. Med. Chem.,2011, 54(7), 2225-40.
78. [78] Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo, Z.; Su, T.; Jiang, H.; Shan, W.; Li, X., Multitarget-directed benzylideneindanonederivatives: anti-beta-amyloid (Abeta) aggregation, antioxidant,metal chelation, and monoamine oxidase B (MAO-B) inhibitionproperties against Alzheimer's disease. J. Med. Chem., 2012,55(19), 8483-92.
79. [79] Liu, K.; Gandhi, R.; Chen, J.; Zhang, S., Bivalent LigandsTargeting Multiple Pathological Factors Involved in Alzheimer'sDisease. ACS Med. Chem. Lett., 2012, 3(11), 942-946.
80. [80] Orlando, R. A.; Gonzales, A. M.; Royer, R. E.; Deck, L. M.; Vander Jagt, D. L., A Chemical Analog of Curcumin as anImproved Inhibitor of Amyloid Abeta Oligomerization. PLoS ONE,2012, 7(3), e31869.
81. [81] Zhang, X.; Tian, Y.; Li, Z.; Tian, X.; Sun, H.; Liu, H.; Moore, A.; Ran, C., Design and Synthesis of Curcumin Analogs for in VivoFluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer’s Disease. J. Amer.Chem. Soc., 2013, 135(44), 16397-16409.
82. [82] Zhang, X.; Tian, Y.; Yuan, P.; Li, Y.; Yaseen, M. A.; Grutzendler, J.; Moore, A.; Ran, C., A bifunctional curcumin analogue for twophotonimaging and inhibiting crosslinking of amyloid beta inAlzheimer's disease. Chem. Comm., 2014, 50(78), 11550-11553.
83. [83] Yang, Y.; Cui, M.; Jin, B.; Wang, X.; Li, Z.; Yu, P.; Jia, J.; Fu, H.; Jia, H.; Liu, B., 99mTc-labeled dibenzylideneacetone derivatives aspotential SPECT probes for in vivo imaging of β-amyloid plaque.Eur. J. Med. Chem., 2013, 64(0), 90-98.
84. [84] Rokka, J.; Snellman, A.; Zona, C.; La Ferla, B.; Nicotra, F.; Salmona, M.; Forloni, G.; Haaparanta-Solin, M.; Rinne, J. O.; Solin, O., Synthesis and evaluation of a 18F-curcumin derivate forβ-amyloid plaque imaging. Bioorg. Med. Chem., 2014, 22(9),2753-2762.
85. [85] Narlawar, R.; Baumann, K.; Schubenel, R.; Schmidt, B., CurcuminDerivatives Inhibit or Modulate Beta-Amyloid Precursor ProteinMetabolism. Neurodegen. Dis., 2007, 4(2-3), 88-93.
86. [86] Narlawar, R.; Pickhardt, M.; Leuchtenberger, S.; Baumann, K.; Krause, S.; Dyrks, T.; Weggen, S.; Mandelkow, E.; Schmidt, B., Curcumin-derived pyrazoles and isoxazoles: Swiss army knives orblunt tools for Alzheimer's disease? Chem. Med. Chem., 2008, 3(1),165-72.
87. [87] Mourtas, S.; Lazar, A.N.; Markoutsa, E.; Duyckaerts, C.; Antimisiaris, S. G., Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potentialapplications for Alzheimer disease. Eur. J. Med. Chem., 2014,80(0), 175-183.
88. [88] Bukhari, S. N. A.; Jantan, I.; Masand, V. H.; Mahajan, D. T.; Sher, M.; Naeem-ul-Hassan, M.; Amjad, M. W., Synthesis of α, β -unsaturated carbonyl based compounds as acetylcholinesterase andbutyrylcholinesterase inhibitors: Characterization, molecularmodeling, QSAR studies and effect against amyloid β -inducedcytotoxicity. Eur. J. Med. Chem., 2014, 83(0), 355-365.